Toxic epidermal necrolysis pathology

Author: Harriet Cheng (BHB, MBChB), Dermatology Unit, Waikato Hospital; Duncan Lamont, Pathologist, Waikato Hospital; A/Prof Patrick Emanuel, Dermatopathologist, Auckland, New Zealand, 2014.

Toxic epidermal necrolysis (TEN) is a severe cutaneous drug reaction characterised by a prodromal 'flu-like illness followed by the rapid appearance of a painful erythematous rash and desquamation of skin and mucous membranes. TEN is at the severe end of a spectrum with Stevens-Johnson syndrome defined by >30% body surface area skin detachment.

Histology of toxic epidermal necrolysis

In TEN, there are subepidermal bullae (Figures 1–3) with widespread epidermal necrosis and subsequent separation or loss of the entire epidermis. Apoptotic keratinocytes may be seen at the periphery (Figure 2, arrow). There is minimal inflammatory infiltrate.

Differential diagnosis of toxic epidermal necrolysis

Erythema multiforme: Apoptotic keratinocytes with less prominent necrosis (may be seen at the centre of established lesions), inflammatory infiltrate is more prominent with lymphocytic perivascular infiltrate.

Phytophototoxic reaction: Marked oedema and subepidermal blistering with apoptotic keratinocytes and epidermal necrosis. Minimal inflammatory infiltrate. Clinical features will easily differentiate from TEN.

Chemotherapy-induced acral erythema: If severe can progress to subepidermal blistering with epidermal necrosis. Clinically distinct from TEN.

Differential diagnosis of cell-poor subepidermal blistering includes variants of epidermolysis bullosa, porphyria cutanea tarda, cell-poor type bullous pemphigoid, burns, suction blisters and some bullous drug reactions.

Related information

Email Newsletter

Would you like to receive our dermatology updates by email?


Submit your images

We're seeking high-quality photos of skin diseases.  


Machine Diagnosis

Watch DermNet's proposal to create a 'Skin Disease Image Recognition Tool' - winner of the 2017 'Clinicians' Challenge Active Award' by the NZ Ministry of Health and HiNZ.

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter